- Home
- MYGN vs CXM Comparison
MYGN vs CXM Comparison
Compare MYGN & CXM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- CXM
- Stock Information
- Founded
- MYGN 1991
- CXM 2009
- Country
- MYGN United States
- CXM United States
- Employees
- MYGN N/A
- CXM N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CXM Computer Software: Prepackaged Software
- Sector
- MYGN Health Care
- CXM Technology
- Exchange
- MYGN Nasdaq
- CXM Nasdaq
- Market Cap
- MYGN 2.0B
- CXM 2.1B
- IPO Year
- MYGN 1995
- CXM 2021
- Fundamental
- Price
- MYGN $12.39
- CXM $8.55
- Analyst Decision
- MYGN Hold
- CXM Hold
- Analyst Count
- MYGN 12
- CXM 15
- Target Price
- MYGN $23.92
- CXM $9.89
- AVG Volume (30 Days)
- MYGN 1.0M
- CXM 1.7M
- Earning Date
- MYGN 02-25-2025
- CXM 12-04-2024
- Dividend Yield
- MYGN N/A
- CXM N/A
- EPS Growth
- MYGN N/A
- CXM 36.57
- EPS
- MYGN N/A
- CXM 0.15
- Revenue
- MYGN $823,600,000.00
- CXM $788,062,000.00
- Revenue This Year
- MYGN $13.82
- CXM $9.55
- Revenue Next Year
- MYGN $4.59
- CXM $3.49
- P/E Ratio
- MYGN N/A
- CXM $56.54
- Revenue Growth
- MYGN 12.15
- CXM 12.02
- 52 Week Low
- MYGN $12.17
- CXM $6.91
- 52 Week High
- MYGN $29.30
- CXM $14.32
- Technical
- Relative Strength Index (RSI)
- MYGN 29.80
- CXM 48.94
- Support Level
- MYGN $12.17
- CXM $8.14
- Resistance Level
- MYGN $15.08
- CXM $8.77
- Average True Range (ATR)
- MYGN 0.79
- CXM 0.26
- MACD
- MYGN -0.01
- CXM -0.03
- Stochastic Oscillator
- MYGN 7.56
- CXM 48.80
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About CXM Sprinklr Inc.
Sprinklr Inc is engaged in providing enterprise software that enables every customer-facing function across the front office, from Customer Care to Marketing, to collaborate across internal silos, and communicate across digital channels. Its products include Sprinklr Service, Sprinklr Social, Sprinklr Insights and Sprinklr Marketing. The company operates in Americas, EMEA and other countries. It derives maximum revenue from Americas.